Paolo Anderlini
Overview
Explore the profile of Paolo Anderlini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
129
Citations
2724
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malek A, Al-Juhaishi T, Milton D, Ramdial J, Daher M, Olson A, et al.
Bone Marrow Transplant
. 2024 Feb;
59(5):699-704.
PMID: 38355908
No abstract available.
2.
Singh H, Srour S, Milton D, McCarty J, Dai C, Gaballa M, et al.
Front Immunol
. 2022 Nov;
13:1032397.
PMID: 36439104
Chimeric antigen receptor (CAR) T-cell therapy has emerged recently as a standard of care treatment for patients with relapsed or refractory acute lymphoblastic leukemia (ALL) and several subtypes of B-cell...
3.
Alatrash G, Saberian C, Bassett R, Thall P, Ledesma C, Lu Y, et al.
Transplant Cell Ther
. 2022 May;
28(8):501.e1-501.e7.
PMID: 35618218
Conditioning regimens play a major role in determining disease outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). The use of i.v. busulfan (Bu) as part of conditioning chemotherapy has been...
4.
Mehta R, Saliba R, Ghanem S, Alousi A, Rondon G, Anderlini P, et al.
Transplant Cell Ther
. 2022 May;
28(7):395.e1-395.e11.
PMID: 35513252
With the use of post-transplantation cyclophosphamide (PTCy), the outcomes of mismatched related donor hematopoietic cell transplantation (HCT) are now approaching those of matched donor HCT. Here we compared haploidentical donor...
5.
Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, et al.
Blood Adv
. 2022 Jan;
6(7):2267-2274.
PMID: 35008100
Secondary central nervous system large B-cell lymphoma (SCNSL) is rare, with a generally poor prognosis. There is limited data about the role of autologous stem cell transplantation (ASCT) in these...
6.
Mehta R, Saliba R, Alsfeld L, Jorgensen J, Wang S, Anderlini P, et al.
Transplant Cell Ther
. 2021 Sep;
27(12):1003.e1-1003.e13.
PMID: 34537419
In the coronavirus disease 19 (COVID-19) pandemic era, the number of haploidentical hematopoietic cell transplantations (HCTs) with peripheral blood (PB) grafts increased significantly compared with HCTs with bone marrow (BM)...
7.
Khouri I, Milton D, Gulbis A, Jabbour E, Nastoupil L, Ledesma C, et al.
Clin Cancer Res
. 2021 Aug;
27(21):5847-5856.
PMID: 34380640
Purpose: To compare outcomes between patients with relapsed follicular lymphoma who received a nonmyeloablative allogeneic stem cell transplant (alloSCT) and those who received an autologous transplant (autoSCT). Patients And Methods:...
8.
Mehta R, Bassett R, Chen J, Valdez B, Kawedia J, Alousi A, et al.
Transplant Cell Ther
. 2021 Jul;
27(11):913.e1-913.e12.
PMID: 34329753
Compared to reduced-intensity conditioning regimen, myeloablative conditioning (MAC) for hematopoietic stem cell transplantation (HCT) reduces relapse but is avoided in older patients because of higher non-relapse mortality (NRM). To meet...
9.
Joseph J, Ma J, Hennawy F, Abdulrazzaq M, Saini N, Patel R, et al.
Transplant Cell Ther
. 2021 May;
27(5):404.e1-404.e5.
PMID: 33965178
The cell of origin (COO) classification into germinal center B cell (GCB) and non-GCB types has been shown to predict survival outcomes in newly diagnosed diffuse large B cell lymphoma...
10.
Nieto Y, Gruschkus S, Valdez B, Jones R, Anderlini P, Hosing C, et al.
Haematologica
. 2021 May;
107(4):899-908.
PMID: 33951890
High-dose chemotherapy and autologous stem-cell transplant (HDC/ASCT) is standard treatment for chemosensitive relapsed classical Hodgkin lymphoma, although outcomes of high-risk relapse (HRR) patients remain suboptimal. We retrospectively analyzed all HRR...